表在性膀胱癌に対するピラルビシン，シタラビン併用膀胱内注入療法の再発予防効果の検討

Postoperative intravesical instillation of pirarubicin (THP) and cytarabine (Ara-C) for superficial bladder tumors：Clinical prophylactic effects on recurrence rate

　60例の表在性膀胱癌症例に対し，TUR-Bt後に再発予防目的として膀胱内注入療法を行った。症例をピラルビシン（THP）単独注入群と，THP・シタラビン（Ara-C）併用注入群に分け，再発予防効果を検討した。57例が検討可能であり，非再発率はそれぞれ，1年：88.4％・96.7％，2年：73.1％・87.1％，3年：69.3％・80.7％であった。THP，Ara-C併用注入群のほうがTHP単独注入群よりも，有意差はないものの高い再発予防効果と再発までの期間延長の傾向が認められた。副作用は両群とも全身的に重篤なものはなく，安全性においてもAra-C併用は従来のTHP単独注入と同等と考えられた。

Prophylactic intravesical instillation of THP and Ara-C was performed in 60 patients with superficial bladder tumor after transurethral resection of the bladder tumor（TUR-Bt）. The patients were grouped into pirarubicin (THP) alone and THP and cytarabine (Ara-C). The efficacy of these intravesical instillations in preventing tumor recurrence was analyzed. There were 57 patients in whom efficacy could be evaluated. After TUR-Bt, the 1-, 2-, and 3-year non-recurrence rates in the group treated with THP alone were 88.4％, 73.1％ and 69.3％ respectively, while in the group treated with THP and Ara-C, the rates were 96.7％, 87.1％ and 80.7％, respectively. Although non-recurrence rates were not statistically significantly different between the two groups, THP and Ara-C appeared to be more effective than THP alone. And the time to recurrence was also prolonged. No severe side effects were observed in any patients. The safety of intravesical instillation of THP and Ara-C was similar to that of THP alone.（Rinsho Hinyokika 62：29-33, 2008）